A Phase 3 interventional study of Atezolizumab and Placebo in Muscle-invasive Bladder Cancer, sponsored by Hoffmann-La Roche. Completed at 140 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing atezolizumab in Urinary Bladder Neoplasms — 1 open to participants now, 11 under way, 2 of them phase 3. atezolizumab · Urinary Bladder Neoplasms.
Among the 21 studies testing atezolizumab in Urinary Bladder Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2021, is one of 6 in phase 3, and was the 19th registered.
1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →1 of the 21 studies testing atezolizumab in Urinary Bladder Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
By country, each count listing its studies:
atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, atezolizumab is the treatment under test here. Read study by study →
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 6
First in 2014; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 761 is above the median of 60 across 1,299 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 96 across the 21 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 21 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 88 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
10 studies in Urinary Bladder Neoplasms by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 10 finished, 9 (90%) have results posted.
Among the 10 studies in Urinary Bladder Neoplasms by Hoffmann-La Roche, this one is the 3rd largest by enrollment, is the only one that started in 2021, is one of 3 in phase 3, and was the 10th registered.
Hoffmann-La Roche’s Urinary Bladder Neoplasms studies by the year they started, since 2014.
4 of the studies testing atezolizumab in Urinary Bladder Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02989584Memorial Sloan Kettering Cancer CenterA Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer | 2026-12 |
| NCT04186013Spanish Oncology Genito-Urinary GroupEfficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer | 2027-02 |
| NCT03237780National Cancer Institute (NCI)Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer | 2027-06-30 |
| NCT05312671Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAtezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies testing atezolizumab in Urinary Bladder Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 10 in Urinary Bladder Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are circulating tumour deoxyribonucleic acid (ctDNA) positive and are at high risk for recurrence following cystectomy.
Inclusion Criteria:
Inclusion Criteria for the Surveillance Phase:
Additional Inclusion Criteria for the Treatment Phase:
Exclusion Criteria:
General Medical Exclusion Criteria for the Surveillance Phase:
Cancer-Specific Exclusion Criteria for the Surveillance Phase:
Additional Exclusion Criteria for the Treatment Phase:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Atezolizumab will be administered intravenously (IV) at a dose of 1680 milligrams (mg) on Day 1 of each 28-day cycle for 12 cycles or up to 1 year (whichever occurs first). Atezolizumab will be discontinued in the event of disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor.
Drug: Atezolizumab · Device: Signatera
Placebo will be administered IV on Day 1 of each 28-day cycle. Placebo will be discontinued in the event of disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor. Following the primary analysis, participants randomized to the comparator arm might discontinue placebo and may receive treatment outside the study at the investigator's discretion.
Other: Placebo · Device: Signatera
Participants who remain ctDNA negative at 12 months from the date of cystectomy will not be randomized to treatment and will enter surveillance follow-up.
Device: Signatera
ctDNA positive participants will receive 1680 mg IV, every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
Also known as: Tecentriq
ctDNA positive participants will receive placebo IV, Q4W on Day 1 of each 28-day cycle
Signatera will be used to evaluate whether ctDNA is detected during serial monitoring of peripheral blood samples for participants enrolled in surveillance. Participants with a ctDNA positive result will be screened for inclusion in the treatment phase. Participants who remain ctDNA negative at 12 months from the date of cystectomy will not be randomized to treatment and will enter surveillance follow-up.
INV-assessed Disease-free Survival (DFS)
INV-assessed DFS was defined as the time from randomization to the first occurrence of a DFS event, defined as any of the following: local (pelvic) recurrence of urothelial carcinoma (UC) (including soft tissue and regional lymph nodes); urinary tract recurrence of UC (including all pathological stages and grades); distant metastasis of UC; or death from any cause. Participants without an INV-assessed DFS event were censored at the last date the participant was assessed to be alive and recurrence-free as determined with radiographic evidence. Kaplan-Meier (KM) methodology was used to estimate the median DFS.
Time frame: From randomization to the first occurrence of a DFS event (Up to 48.2 months)
Overall Survival (OS)
OS was defined as the time from randomization to death from any cause. Data for participants who did not die at the time of analysis were censored at the date last known to be alive. Data for participants who did not have post-baseline information were censored at the date of randomization. KM methodology was used to estimate the median OS.
Time frame: From randomization to death from any cause (Up to 48.2 months)
Independent Review Facility (IRF)-Assessed DFS
IRF-assessed DFS was defined as the time from randomization to the first occurrence of a DFS event, defined as any of the following: local (pelvic) recurrence of UC (including soft tissue and regional lymph nodes); urinary tract recurrence of UC (including all pathological stages and grades); distant metastasis of UC; or death from any cause. Participants without an IRF-assessed DFS event were censored at the last date the participant was assessed to be alive and recurrence-free as determined with radiographic evidence. KM methodology was used to estimate the median DFS.
Time frame: From randomization to the first occurrence of a DFS event (Up to 48.2 months)
INV-assessed Disease-specific Survival (DSS)
INV-assessed DSS was defined as the time from randomization to death from UC per investigator assessment of cause of death. Data for participants who did not die will be censored at the last date they were known to be alive. Data for participants who died from causes other than bladder cancer were censored at the date of death. KM methodology was used to estimate the median DSS.
Time frame: From randomization to death from UC (Up to 48.2 months)
INV-assessed Distant Metastasis-free Survival (DMFS)
INV-assessed DMFS was defined as the time from randomization to the first occurrence of a DMFS event, defined as diagnosis of distant (i.e., non-locoregional) metastasis or death from any cause. Data for participants without a DMFS event were censored at the last date the participant was assessed to be alive and free of distant metastasis. Data for participants with no post-baseline disease assessment were censored at the randomization date. KM methodology was used to estimate the median DMFS.
Time frame: From randomization to the first occurrence of a DMFS event (Up to 48.2 months)
Time to Confirmed Deterioration (TTCD) in Physical Functioning, Role Functioning & Global Health Status/Quality of Life (GHS/QoL), Assessed by European Organisation for Research & Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
TTCD of physical functioning (PF), role functioning (RF) \& health-related quality of life (HRQoL) was defined as time from randomization to first documented confirmed deterioration. Confirmed deterioration=participant's first ≥10-point score decrease from baseline on EORTC QLQ C30 PF, RF or GHS/QoL scale that must be held for ≤2 consecutive time points or followed by death due to cancer progression within 8 weeks from last patient-reported outcomes (PRO) assessment. EORTC QLQ-C30 has 30 questions assessing 5 aspects of participant functioning (physical, emotional, role, cognitive \& social), 3 symptom scales (fatigue, nausea \& vomiting \& pain), GHS/QoL \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning items are scored on a 4-point scale (1=Not at All to 4=Very Much) \& GHS/QoL on a 7-point scale (1=very poor to 7=excellent). Scores are linearly transformed on a scale of 0 to 100. High score=better functioning/better QoL.
Time frame: Up to 11.8 months
Percentage of Participants With ctDNA Clearance
ctDNA clearance was defined as the percentage of participants who were ctDNA positive at baseline and ctDNA negative at Cycle 3, Day 1 or Cycle 5, Day 1. Percentages have been rounded off.
Time frame: Baseline, Day 1 of Cycles 3 or 5 (Cycle length = 28 days)
Number of Participants With Adverse Events (AEs)
AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: From initiation of study treatment up to approximately 5 years
Maximum Serum Concentration (Cmax) of Atezolizumab
Time frame: 30 minutes post dose on Cycle 1 Day 1 (Cycle length = 28 days)
Minimum Serum Concentration (Cmin) of Atezolizumab
Time frame: Pre-dose on Day 1 of Cycles 2, 3, 4, 8 and 12 (Cycle length = 28 days)
Number of Participants With Anti-drug Antibodies (ADAs) to Atezolizumab
Participants who received atezolizumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following atezolizumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.
Time frame: Up to 12.8 months
A total of 761 participants with high-risk muscle-invasive bladder cancer (MIBC) who underwent radical cystectomy were enrolled in the surveillance phase of the study after confirming no radiographic evidence of residual disease. Patients were eligible regardless of whether they had received prior platinum-based neoadjuvant chemotherapy (NAC). Participants were enrolled at 157 investigative sites across 24 countries. The study is still ongoing.
| Milestone | Surveillance Phase | Placebo | Atezolizumab |
|---|---|---|---|
| Started | 761 | 0 | 0 |
| Ctdna negative participants | 377 | 0 | 0 |
| Completed | 307 | 0 | 0 |
| Not completed | 454 | 0 | 0 |
| Withdrew: Ctdna negative participants - ongoing in surveillance phase | 8 | 0 | 0 |
| Withdrew: Ctdna status unknown | 5 | 0 | 0 |
| Withdrew: Ctdna positive screened for treatment phase | 379 | 0 | 0 |
| Withdrew: Withdrawal by subject | 21 | 0 | 0 |
| Withdrew: Investigator (inv)-assessed disease recurrence | 19 | 0 | 0 |
| Withdrew: Death | 11 | 0 | 0 |
| Withdrew: Protocol violation | 6 | 0 | 0 |
| Withdrew: Physician decision | 4 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Milestone | Surveillance Phase | Placebo | Atezolizumab |
|---|---|---|---|
| Started | 0 | 83 | 167 |
| Safety-evaluable (se) population | 0 | 83 | 165 |
| Efficacy analysis population | 0 | 83 | 167 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 83 | 167 |
| Withdrew: Death | 0 | 36 | 60 |
| Withdrew: Withdrawal by subject | 0 | 8 | 7 |
| Withdrew: Ongoing in study | 0 | 39 | 100 |
INV-assessed DFS was defined as the time from randomization to the first occurrence of a DFS event, defined as any of the following: local (pelvic) recurrence of urothelial carcinoma (UC) (including soft tissue and regional lymph nodes); urinary tract recurrence of UC (including all pathological stages and grades); distant metastasis of UC; or death from any cause. Participants without an INV-assessed DFS event were censored at the last date the participant was assessed to be alive and recurrence-free as determined with radiographic evidence. Kaplan-Meier (KM) methodology was used to estimate the median DFS.
| months | Placebo | Atezolizumab |
|---|---|---|
| INV-assessed Disease-free Survival (DFS) | 4.83 (4.07 to 8.34) | 9.86 (7.16 to 12.71) |
OS was defined as the time from randomization to death from any cause. Data for participants who did not die at the time of analysis were censored at the date last known to be alive. Data for participants who did not have post-baseline information were censored at the date of randomization. KM methodology was used to estimate the median OS.
| months | Placebo | Atezolizumab |
|---|---|---|
| Overall Survival (OS) | 21.13 (14.65 to NA) | 32.79 (27.66 to NA) |
IRF-assessed DFS was defined as the time from randomization to the first occurrence of a DFS event, defined as any of the following: local (pelvic) recurrence of UC (including soft tissue and regional lymph nodes); urinary tract recurrence of UC (including all pathological stages and grades); distant metastasis of UC; or death from any cause. Participants without an IRF-assessed DFS event were censored at the last date the participant was assessed to be alive and recurrence-free as determined with radiographic evidence. KM methodology was used to estimate the median DFS.
| months | Placebo | Atezolizumab |
|---|---|---|
| Independent Review Facility (IRF)-Assessed DFS | 6.24 (4.11 to 8.34) | 9.30 (6.14 to 10.41) |
INV-assessed DSS was defined as the time from randomization to death from UC per investigator assessment of cause of death. Data for participants who did not die will be censored at the last date they were known to be alive. Data for participants who died from causes other than bladder cancer were censored at the date of death. KM methodology was used to estimate the median DSS.
| months | Placebo | Atezolizumab |
|---|---|---|
| INV-assessed Disease-specific Survival (DSS) | NA (18.20 to NA) | NA (32.79 to NA) |
INV-assessed DMFS was defined as the time from randomization to the first occurrence of a DMFS event, defined as diagnosis of distant (i.e., non-locoregional) metastasis or death from any cause. Data for participants without a DMFS event were censored at the last date the participant was assessed to be alive and free of distant metastasis. Data for participants with no post-baseline disease assessment were censored at the randomization date. KM methodology was used to estimate the median DMFS.
| months | Placebo | Atezolizumab |
|---|---|---|
| INV-assessed Distant Metastasis-free Survival (DMFS) | 9.66 (6.51 to 13.27) | 14.09 (10.41 to 19.29) |
TTCD of physical functioning (PF), role functioning (RF) \& health-related quality of life (HRQoL) was defined as time from randomization to first documented confirmed deterioration. Confirmed deterioration=participant's first ≥10-point score decrease from baseline on EORTC QLQ C30 PF, RF or GHS/QoL scale that must be held for ≤2 consecutive time points or followed by death due to cancer progression within 8 weeks from last patient-reported outcomes (PRO) assessment. EORTC QLQ-C30 has 30 questions assessing 5 aspects of participant functioning (physical, emotional, role, cognitive \& social), 3 symptom scales (fatigue, nausea \& vomiting \& pain), GHS/QoL \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning items are scored on a 4-point scale (1=Not at All to 4=Very Much) \& GHS/QoL on a 7-point scale (1=very poor to 7=excellent). Scores are linearly transformed on a scale of 0 to 100. High score=better functioning/better QoL.
| months | Placebo | Atezolizumab |
|---|---|---|
| PF | NA (19.35 to NA) | 25.13 (18.46 to NA) |
| RF | NA (19.35 to NA) | 18.46 (12.22 to NA) |
| GHS/QoL | 16.49 (10.87 to NA) | 35.42 (19.25 to NA) |
ctDNA clearance was defined as the percentage of participants who were ctDNA positive at baseline and ctDNA negative at Cycle 3, Day 1 or Cycle 5, Day 1. Percentages have been rounded off.
| percentage of participants | Placebo | Atezolizumab |
|---|---|---|
| Percentage of Participants With ctDNA Clearance | 14.5 (7.70 to 23.89) | 25.1 (18.77 to 32.44) |
AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Results for this outcome have not been posted.
| micrograms per milliliter (μg/mL) | Atezolizumab |
|---|---|
| Maximum Serum Concentration (Cmax) of Atezolizumab | 500 ± 26.7 |
| μg/mL | Atezolizumab |
|---|---|
| Pre-dose on Cycle 2 Day 1 | 85.3 ± 40.9 |
| Pre-dose on Cycle 3 Day 1 | 114 ± 92.3 |
| Pre-dose on Cycle 4 Day 1 | 145 ± 43.2 |
| Pre-dose on Cycle 8 Day 1 | 184 ± 40.5 |
| Pre-dose on Cycle 12 Day 1 | 205 ± 49.8 |
Participants who received atezolizumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following atezolizumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.
| Participants | Atezolizumab |
|---|---|
| Number of Participants With Anti-drug Antibodies (ADAs) to Atezolizumab | 45 |
Collected over AEs and SAEs: From initiation of study treatment up to 14.7 months; All-Cause Mortality: Up to 48.2 months; Data collected up to the primary completion date is being reported here. Data collection is still ongoing, and final data will be reported one year after the study completion date. All-cause mortality: Efficacy analysis population (Treatment Phase). All enrolled participants (Surveillance Phase).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Surveillance Phase | 11/761 (1.4%) | — | — |
| Placebo | 36/83 (43.4%) | 17/83 (20.5%) | 54/83 (65.1%) |
| Atezolizumab | 60/167 (35.9%) | 44/165 (26.7%) | 107/165 (64.8%) |
| Event | Surveillance Phase | Placebo | Atezolizumab |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | — | 4/83 | 10/165 |
| PyelonephritisInfections and infestations | — | 0/83 | 4/165 |
| IleusGastrointestinal disorders | — | 2/83 | 3/165 |
| HydronephrosisRenal and urinary disorders | — | 2/83 | 0/165 |
| Intestinal obstructionGastrointestinal disorders | — | 0/83 | 3/165 |
| Acute kidney injuryRenal and urinary disorders | — | 0/83 | 3/165 |
| Inguinal herniaGastrointestinal disorders | — | 0/83 | 2/165 |
| SepsisInfections and infestations | — | 1/83 | 2/165 |
| Renal failureRenal and urinary disorders | — | 0/83 | 2/165 |
| Arteriosclerosis coronary arteryCardiac disorders | — | 1/83 | 0/165 |
| Event | Surveillance Phase | Placebo | Atezolizumab |
|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | — | 9/83 | 29/165 |
| Urinary tract infectionInfections and infestations | — | 10/83 | 25/165 |
| AnaemiaBlood and lymphatic system disorders | — | 3/83 | 20/165 |
| AstheniaGeneral disorders | — | 10/83 | 15/165 |
| FatigueGeneral disorders | — | 10/83 | 18/165 |
| ConstipationGastrointestinal disorders | — | 6/83 | 18/165 |
| DiarrhoeaGastrointestinal disorders | — | 9/83 | 15/165 |
| Blood creatinine increasedInvestigations | — | 9/83 | 13/165 |
| HypothyroidismEndocrine disorders | — | 1/83 | 17/165 |
| PyrexiaGeneral disorders | — | 8/83 | 9/165 |
Placebo and Atezolizumab arms: Efficacy analysis population included all participants randomized to receive study treatment regardless of the length of time between cystectomy and ctDNA positive status, when the primary analysis of DFS was conducted. Surveillance Participants: All participants other than those included in the efficacy analysis population.
| Age, Categorical(Participants) | Surveillance Participants (Not Randomized) | Placebo | Atezolizumab | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 163 | 35 | 50 | 248 |
| >=65 years | 348 | 48 | 117 | 513 |
| Sex: Female, Male(Participants) | Surveillance Participants (Not Randomized) | Placebo | Atezolizumab | Total |
|---|---|---|---|---|
| Female | 124 | 16 | 26 | 166 |
| Male | 387 | 67 | 141 | 595 |
| Ethnicity (NIH/OMB)(Participants) | Surveillance Participants (Not Randomized) | Placebo | Atezolizumab | Total |
|---|---|---|---|---|
| Hispanic or Latino | 45 | 9 | 19 | 73 |
| Not Hispanic or Latino | 435 | 70 | 141 | 646 |
| Unknown or Not Reported | 31 | 4 | 7 | 42 |
| Race (NIH/OMB)(Participants) | Surveillance Participants (Not Randomized) | Placebo | Atezolizumab | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 7 | 0 | 4 | 11 |
| Asian | 188 | 27 | 52 | 267 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 0 | 2 |
| Black or African American | 8 | 2 | 0 | 10 |
| White | 276 | 50 | 104 | 430 |
| More than one race | 2 | 0 | 0 | 2 |
| Unknown or Not Reported | 28 | 4 | 7 | 39 |
Showing the first 100 of 140 sites across 23 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from May 2021 to primary completion in Jun 2025, 49 months.
Results were first posted in Sep 2026, 1 year 3 months after primary completion.
Of 39 industry-sponsored phase 3 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 74. This study's 49 months is close to that.
Counting every sponsor, half of 73 studies reached it within 65 months; a quarter within 40 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atezolizumab